GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Cerus Corp (NAS:CERS) » Definitions » Tangible Book per Share

Cerus (CERS) Tangible Book per Share : $0.28 (As of Dec. 2023)


View and export this data going back to 1997. Start your Free Trial

What is Cerus Tangible Book per Share?

Tangible book value per share is calculated as the total tangible equity divided by Shares Outstanding (EOP). Total tangible equity is calculated as the Total Stockholders Equity minus Preferred Stock minus Intangible Assets. Cerus's tangible book value per share for the quarter that ended in Dec. 2023 was $0.28.

Since intangibles such as goodwill cannot be sold when the company liquidates, tangible book value per share is considered more accurate in reflecting how much shareholders will receive when the company liquidates.


Cerus Tangible Book per Share Historical Data

The historical data trend for Cerus's Tangible Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cerus Tangible Book per Share Chart

Cerus Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Tangible Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.39 0.61 0.48 0.37 0.28

Cerus Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Tangible Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.37 0.32 0.27 0.26 0.28

Competitive Comparison of Cerus's Tangible Book per Share

For the Medical Devices subindustry, Cerus's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cerus's Price-to-Tangible-Book Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Cerus's Price-to-Tangible-Book distribution charts can be found below:

* The bar in red indicates where Cerus's Price-to-Tangible-Book falls into.



Cerus Tangible Book per Share Calculation

Cerus's Tangible Book Value Per Share for the fiscal year that ended in Dec. 2023 is calculated as

Tangible Book Value per Share=(Total Stockholders Equity-Preferred Stock-Intangible Assets)/Shares Outstanding (EOP)
=(52.65-0-1.316)/181.248
=0.28

Cerus's Tangible Book Value Per Share for the quarter that ended in Dec. 2023 is calculated as

Tangible Book Value per Share=(Total Stockholders Equity-Preferred Stock-Intangible Assets)/Shares Outstanding (EOP)
=(52.65-0-1.316)/181.248
=0.28

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Theoretically it is what the shareholders will receive if the company is liquidated. Total equity is a balance sheet item and equal to total assets less total liabilities of the company. Since intangibles such as goodwill cannot be sold when the company liquidates, tangible book value per share is considered more accurate in reflecting how much shareholders will receive when the company liquidates.


Cerus  (NAS:CERS) Tangible Book per Share Explanation

Usually a company's book value and Tangible Book per Share may not reflect its true value. The assets may be carried on the balance sheets at the original cost minus depreciation. This may underestimate the true economic values of the assets. It also may over-estimate their true economic value because the assets can become obsolete.

For financial companies such as banks and insurance companies, their assets may be reported in current market value of the assets owned. Book values of financial companies are more accurate indicator of the economic value of the company.


Cerus Tangible Book per Share Related Terms

Thank you for viewing the detailed overview of Cerus's Tangible Book per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Cerus (CERS) Business Description

Traded in Other Exchanges
Address
1220 Concord Avenue, Suite 600, Concord, CA, USA, 94520
Cerus Corp is a biomedical products company focused on the field of blood transfusion safety. The INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria, and parasites. The company sells its INTERCEPT platelet and plasma systems in the United States of America, Europe, the Commonwealth of Independent States countries, the Middle East, and selected countries in other regions around the world. The firm continues to operate in only one segment: Blood safety and generates revenue from the same.
Executives
Eric Bjerkholt director 132 PURDURE AVENUE, KENGSINGTON CA 94708
Ann Lucena director C/O CERUS CORPORATION, 1220 CONCORD AVE. SUITE 600, CONCORD CA 94520
Swisher Daniel N Jr director C/O SUNESIS PHARMACEUTICALS, INC., 395 OYSTER POINT BLVD., SUITE 400, SOUTH SAN FRANCISCO CA 94080
Gail Schulze director 3451 WELLS ROAD, MALVERN PA 19355
Laurence M Corash director C/O CERUS CORP, 2411 STENWELL DRIVE, CONCORD CA 94520
William Mariner Greenman officer: President, Cerus Europe C/O CERUS CORPORATION, 2411 STANWELL DRIVE, CONCORD CA 94520
Chrystal Menard officer: Chief Legal Officer C/O CERUS CORPORATION, 2550 STANWELL DRIVE, CONCORD CA 94520
Kevin Dennis Green officer: Chief Accounting Officer C/O CERUS CORPORATION, 2411 STANWELL DRIVE, CONCORD CA 94520
Richard J Benjamin officer: Chief Medical Officer 15 WHITE PINE ROAD, NEWTON MA 02464
Vivek K Jayaraman officer: Chief Commercial Officer 3910 BRICKWAY BLVD, SANTA ROSA CA 95403
Hua Shan director C/O CERUS CORPORATION, 1220 CONCORD AVE., STE. 600, CONCORD CA 94520
Carol Moore officer: SR. V.P. Regulatory, Clinical C/O CERUS CORPORATION, 2550 STANWELL DRIVE, CONCORD CA 94520
Timothy B Anderson director C/O JAN STERN REED BAXTER INTERNATIONAL, ONE BAXTER PARKWAY DF2 2W, DEERFIELD IL 60015
Timothy L. Moore director C/O KITE PHARMA, INC., 2225 COLORADO AVE., SANTA MONICA CA 90404
Frank Witney director 940 WINTER STREET, C/O PERKINELMER, WALTHAM MA 02451